OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2025-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to increase diabetic retinopathy screening rates to 70.3%. Research indicates that low screening rates are associated with a variety of factors, including income levels, race and lack of access to care. Furthermore, because diabetic retinopathy frequently presents asymptomatically, non-adherence to screening results in postponed disease detection and a higher probability of vision loss. Currently, it is estimated that 9 million adults in the US are affected by diabetic retinopathy, and 1.8 million suffer from vision-threatening diabetic retinopathy. Importantly, the rates of vtDR vary greatly by race, with Hispanic individuals at 7.14% and Black individuals at 8.66%, compared to 3.55% in White individuals. Despite these alarming figures, the disease can be managed and vision loss can often be averted with early disease detection, thus highlighting the importance of increasing screening rates.

A clear need exists for a diabetic retinopathy screening tool that can be deployed in primary care settings, addressing the shortage of specialist care and making screening more accessible to underserved populations. OPTDR01 will directly address these issues by providing accessible, high quality screening for diabetic retinopathy. OPTDR01 will automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in diabetic adults who have not previously been diagnosed with mtmDR or vtDR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Computer-based Screening for Diabetic Retinopathy

NCT01614327

Diabetic Retinopathy

COMPLETED

Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening

NCT06879834

Diabetic Retinopathy

RECRUITING

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

NCT07151001

Diabetes Diabetic Retinopathy

RECRUITING

RetinaVue Diabetic Screening

NCT03343730

Diabetic Retinopathy

UNKNOWN NA

A Multi-center Study on the Artificial Intelligence Enabled Diabetic Retinopathy Screening Based on Fundus Images

NCT03602989

Diabetic Retinopathy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted to assess the feasibility of the OPTDR01 in detecting mtmDR and vtDR in frontline care settings in adults with a diagnosis of diabetes but no prior diagnosis of diabetic retinopathy. The study will inform the design of a large pivotal study in terms of expected disease prevalence, participant recruitment rate, data collection tools and study workflow.

Eligible participants will undergo the following:

* retinal imaging sessions of each eye with a fundus camera for OPTDR01 evaluation
* dilation with mydriatic agent
* fundus photography, macular optical coherence tomography (OCT) and red reflex exam of each eye for comparison.

A subset of participants will be invited to participate in a precision sub-study, during which multiple operators will image participant eyes with multiple cameras.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retinal imaging

Participants will undergo retinal imaging with and without mydriatic agent to dilate the pupils.

OPTDR01 software application

Intervention Type DEVICE

Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OPTDR01 software application

Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Having met the criteria established by either the World Health Organization (WHO) or the American Diabetes Association (ADA):
2. Age 22 or older
3. Understand the study and volunteer to sign the informed consent

Exclusion Criteria

1. Unable to understand the study
2. Unwilling to sign informed consent
3. Indicate persistent vision loss, blurred vision, or floaters
4. Previous diagnosis of macular edema, diabetic retinopathy (any level) proliferative retinopathy, radiation retinopathy, or retinal vein occlusion
5. History of laser treatment of the retina or injections into either eye, or any history of retinal surgery
6. Currently participating in another investigational eye study or actively receiving investigational product for diabetic retinopathy or diabetic macular edema
7. A condition that, in the opinion of the investigator, would preclude participation in the study
8. Contraindicated for imaging by fundus imaging systems used in the study because of hypersensitivity to light, recently underwent photodynamic therapy, or was taking medication that causes photosensitivity
9. Known pregnancy

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No